Tags |
|
|
Links |
|
|
Digg It - Medical Billing - XA0 Record Fields 18 Through 23
Trailer records are a subtle animal. They don't seem to do much, but in the world of medical billing and the electronic transmission of claims, trai
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ler records can mean the difference between a whole claim file going through or being rejected like a bad virus. In this installment of our series o
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
n medical billing and electronic claims submission, we'll be continuing our review of the XA0 record, picking up with field number 18.
XA0 field 18,
XA0 field 18,
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
positions 120 - 126, is the total payer paid amount. This is the total amount of all claims being billed that have already been paid by the primary
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
payer. For those wondering how this can even be possible, it is not uncommon for a claim to be partially paid by a payer and then rebilled by the pr
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ovider in an attempt to get the outstanding balance paid off. In some cases, given the proper documentation, the remaining balance may be paid, but
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
not often and certainly not always.
XA0 field 19, positions 127 - 133, is the total patient paid amount. This is the total amount of all claims bei
XA0 field 19, positions 127 - 133, is the total patient paid amount. This is the total amount of all claims bei
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
g billed where the patient has made payments towards the claims themselves. This is mostly for the purpose of reimbursing the patient back on any cl
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
aims where the services are covered. If they are not, then the patient is still responsible for the payments.
XA0 field 20, positions 134 - 140, is
XA0 field 20, positions 134 - 140, is
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
the total purchased services charges. This is the total charges for all purchased services. The reason this is broken out is because not all servi
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
es are considered purchased services. Just don't go looking for an explanation in the manual for why this information is needed by the insurance car
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
rier as it has no effect on the amount that is paid on the claims themselves.
XA0 field 21, positions 141 - 156, is the provider discount informatio
XA0 field 21, positions 141 - 156, is the provider discount informatio
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
n. This field is currently not supported by NSF 3.01 specifications and will not be covered in this article. Refer to your manual for an explanatio
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
n of what this field is for.
XA0 field 22, positions 157 - 259, is the claim remarks field. This is another one of those fields that is rarely used
XA0 field 22, positions 157 - 259, is the claim remarks field. This is another one of those fields that is rarely used
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
but if needed can cause lots of problems. This field is used to enter in any supportive information needed in the processing of the claims. These
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
informational remarks must be entered in accordance with the format specified by the individual carrier being billed. Because all carriers have diff
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
erent requirements, it is important to check with the one you are billing to get the proper format.
XA0 field 23, positions 260 - 320, is national f
XA0 field 23, positions 260 - 320, is national f
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ller and must be filled with spaces or the entire claim file will be rejected for that particular patient. It will however, not have any effect on o
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ther patient records.
The XA0 record doesn't seem to do very much but just add up some totals, but without it, a patient's claims, up to 99 per file
The XA0 record doesn't seem to do very much but just add up some totals, but without it, a patient's claims, up to 99 per file
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
, will not be paid. In our next installment on medical billing we'll begin our coverage of the next in our series of trailer records, the YA0 record
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/2022/diggit-Medical-Billing--XA0-Record-Fields-18-Through-23.html">Medical Billing - XA0 Record Fields 18 Through 23</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/2022/diggit-Medical-Billing--XA0-Record-Fields-18-Through-23.html]Medical Billing - XA0 Record Fields 18 Through 23[/url]
Related Articles:
Dealing With The Public-Not Always A Barrel Of Monkeys!
Appealing to Four Categories of B2B Decision-Makers
Bookmark it:
|